Condition: Crohn's Disease · Ulcerative Colitis · Sponsor: AbbVie
Inflammatory Bowel Disease (IBD), encompassing Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic, relapsing, and often disabling condition characterized by inflammation of the gastrointestinal tract. A treat-to-target strategy (T2T) is recommended by international guidelines to optimize long-term outcomes in IBD. The purpose of this study is to describe the real-life implementation of T2T in IBD worldwide and the association between using a T2T strategy and disease outcomes. This is a multi-country, observational, retrospective (non-interventional) study with a cross-sectional component based upon a sample of adult participants with IBD. All objectives will be assessed for IBD and then for CD/UC separately. Primary and secondary objectives will be assessed for the overall population over the 24 months study period. As this is an observational study, enrolled participants will be managed and followed up according to the standard practice. Retrospective chart review over the 24-months from date of inclusion will allow us to collect the variables of interest by using an e-CRF. There will be no additional burden for participants in this trial. Study visits will not be required as this is a retrospective chart review.
This description comes directly from the study's public registry record.
Colla Cunneen · 708-650-3696 · colla.cunneen@abbvie.com
Always discuss trial participation with your own doctor first.
| Chongqing General Hospital /ID# 282777 | Chongqing, Chongqing Municipality, China | Recruiting |
| Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau /ID# 282775 | Nîmes, Gard, France | Not Yet Recruiting |
| Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois /ID# 280265 | Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France | Not Yet Recruiting |
| CHU Amiens-Picardie Site Sud /ID# 280263 | Amiens, Somme, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07421258